Ruairidh MaciverBBC Naidheachdan
Getty ImagesEighty years ago a small crowd gathered in a hall in Tobermory on Mull for a preview…

Ruairidh MaciverBBC Naidheachdan
Getty ImagesEighty years ago a small crowd gathered in a hall in Tobermory on Mull for a preview…

Investors who take an interest in Bridgepoint Group plc (LON:BPT) should definitely note that the Independent Non-Executive Director, Cyrus Russi Taraporevala, recently paid UK£2.84 per share to buy UK£284k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 100%, potentially signalling some real optimism.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.
Notably, that recent purchase by Cyrus Russi Taraporevala is the biggest insider purchase of Bridgepoint Group shares that we’ve seen in the last year. That means that an insider was happy to buy shares at above the current price of UK£2.72. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it’s very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Cyrus Russi Taraporevala.
The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Bridgepoint Group
Bridgepoint Group is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Based on our data, Bridgepoint Group insiders have about 0.1% of the stock, worth approximately UK£2.3m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We prefer to see high levels of insider ownership.
It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. While the overall levels of insider ownership are below what we’d like to see, the history of transactions imply that Bridgepoint Group insiders are reasonably well aligned, and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it’s also worthwhile knowing the risks facing this company. Our analysis shows 3 warning signs for Bridgepoint Group (1 is significant!) and we strongly recommend you look at these before investing.

Oceaneering International (OII) has caught some attention lately as its stock edged higher, gaining about 3% in the latest session. This uptick comes even as the broader energy sector presented mixed signals for investors.
See our latest analysis for Oceaneering International.
Oceaneering International’s recent share price gain builds on a gradually improving short-term trend, but momentum is still muted compared to last year’s performance. While the stock is up 3.29% in the last session, the one-year total shareholder return sits at -19.58%. This reminds investors of some lingering caution, even after impressive multi-year gains.
If you’re keeping an eye on shifts in energy sector momentum, now is the perfect chance to broaden your search and discover fast growing stocks with high insider ownership
With shares staging a modest rebound, the question now is whether Oceaneering International remains undervalued with more upside ahead, or if investors have already factored in future growth prospects at current levels.
At $24.15 per share, Oceaneering International trades just above the consensus narrative fair value of $22.38, suggesting that the market anticipates robust operational progress and stable growth prospects.
The company’s high dependency on cyclical offshore oil and gas spending, evident in bookings and utilization guidance, makes its revenues and earnings vulnerable to potential sharp downturns if energy prices fall or if capital expenditure plans of major clients decline, as indicated by flat book-to-bill ratios and conservative utilization outlooks.
Read the complete narrative.
What hidden numbers are driving analyst models this time? The narrative is based on detailed assumptions about future revenue streams, margin pressures, and strategic pivots that could change profits more rapidly than many anticipate. Want to know what financial forecasts are influencing this price target? Find out what could surprise investors by reading the full breakdown.
Result: Fair Value of $22.38 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, continued growth in aerospace and defense contracts, or persistent strength in high-margin robotics, could boost earnings beyond current expectations.
Find out about the key risks to this Oceaneering International narrative.
While the market sees Oceaneering International as slightly overvalued based on analyst price targets, our DCF model presents a very different story. The SWS DCF model estimates fair value at $51.12, which is more than double the current share price. This suggests considerable undervaluation. Could analysts be overlooking hidden future cash flows?

If you have ever taken large doses of vitamin C to boost immunity or recover from a cold, you are not alone. Many people assume vitamin C is completely harmless because it is water-soluble and the body flushes out whatever it does not need. But…

Dave (DAVE) shares have experienced some notable ups and downs over the past month, catching the attention of investors watching the stock’s performance. Recent price shifts prompt a closer look at how the company is positioned in today’s market.
See our latest analysis for Dave.
Dave’s recent 6.7% jump in share price came after weeks of choppy trading, including a noticeable slide earlier in the month. Even with this volatility, momentum remains strong, as shown by its impressive year-to-date share price return of 125.56% and a truly staggering total shareholder return of 1,383.84% over the past three years.
If you’re open to finding other remarkable growth stories in today’s market, now is the perfect moment to broaden your perspective and discover fast growing stocks with high insider ownership
But with Dave’s current share price still trading well below analysts’ targets, the key question remains: does this signal an undervalued opportunity, or has the market already factored in the company’s growth prospects?
With Dave’s last closing price standing well below its most popular narrative’s fair value, debate is swirling on what’s truly fueling this perceived upside. As analysts weigh enthusiasm against new profitability forecasts, one insight stands out as a defining catalyst.
Enhanced monetization from fee structure changes, including a successful rollout of a $3 monthly subscription fee (with no measurable negative impact on retention), offers meaningful ARPU and LTV uplift, further supported by secular demand for transparent, low-fee banking alternatives. This directly supports revenue growth and margin expansion.
Read the complete narrative.
Want to know what’s behind this big valuation gap? The narrative pivots on bold fee strategies, new margin targets, and revenue projections that defy industry norms. Ready to see the financial leap that drives this astounding fair value?
Result: Fair Value of $285 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are still questions about tightening regulations on fee-based models. There is also the possibility that shifting consumer preferences could dampen demand.
Find out about the key risks to this Dave narrative.
If you see things differently or want to conduct your own research, it only takes a few minutes to build your own perspective. Do it your way
A great starting point for your Dave research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

A NOVEL study has shown that Glucagon-like peptide-1 (GLP-1) agonists, medications widely used for obesity and type 2 diabetes, may offer benefits for patients with hidradenitis suppurativa (HS), a chronic inflammatory skin condition often…

The Silver Sliver Galaxy is a lovely sight in Andromeda the Princess. View this edge-on spiral in a dark sky with no Moon later tonight.

Something in the US economy isn’t adding up, and it’s rattling the people charged with wrangling inflation and keeping the labor market intact.
US companies have sharply slowed their hiring this year, hesitant to invest without knowing the full effects of President Donald Trump’s sweeping economic policies. The economy lost jobs in June and August, and the average pace of job gains for the three months ending in September was only around 62,000, according to the Labor Department.
Yet workers’ productivity, a key driver of economic output, remains high. And gross domestic product, which captures all the goods and services produced in the economy, has stayed robust.
That dichotomy of an expanding economy and a softening labor market presents a conundrum for policymakers at the Federal Reserve, complicating their efforts to determine whether the economy needs cooling or boosting.
“The divergence between solid economic growth and weak job creation created a particularly challenging environment for policy decisions,” Fed officials noted in their October meeting, according to minutes released Thursday.
A growing economy, boosted by resilient consumers and massive investments in AI, should be spurring hiring, especially now that the Fed has started lowering borrowing costs. But that hasn’t happened, and there are fears it won’t.
“When it comes to monetary policy, the narrative next year is going to be about how to handle a jobless expansion,” Ryan Sweet, chief US economist at Oxford Economics, told CNN. “How do you try to get businesses to hire more?”
The recent string of record highs in the stock market suggests that many American businesses are optimistic about the value of AI. However, that confidence has so far not translated into an expansion of their workforce.
Business spending on information processing equipment and software accounted for 4.4% of GDP in the second quarter, according to Commerce Department data, slightly below a peak reached in 2000 when businesses ramped up similar investments during the dot-com boom. Solid consumer spending this year has also kept company profits afloat.
“Firms are investing a lot in this new technology, but sometimes that means reducing other expenditures, such as hiring,” said Eugenio Alemán, chief economist at Raymond James. He added that strong AI investment likely persisted in the third quarter and should peak sometime next year.
The government shutdown likely dented GDP in the current quarter that stretches from October through December, but the US economy is widely expected to recoup most of those losses early next year.

Using the 2 Stage Free Cash Flow to Equity, iomart Group fair value estimate is UK£0.28
Current share price of UK£0.26 suggests iomart Group is potentially trading close to its fair value
Analyst price target for IOM is UK£0.53, which is 87% above our fair value estimate
Today we will run through one way of estimating the intrinsic value of iomart Group plc (LON:IOM) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. There’s really not all that much to it, even though it might appear quite complex.
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second ‘steady growth’ period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren’t available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today’s dollars:
|
2026 |
2027 |
2028 |
2029 |
2030 |
2031 |
2032 |
2033 |
2034 |
2035 |
|
|
Levered FCF (£, Millions) |
UK£200.0k |
UK£3.30m |
UK£6.40m |
UK£5.20m |
UK£4.56m |
UK£4.21m |
UK£4.02m |
UK£3.93m |
UK£3.90m |
UK£3.92m |
|
Growth Rate Estimate Source |
Analyst x2 |
Analyst x2 |
Analyst x1 |
Est @ -18.80% |
Est @ -12.26% |
Est @ -7.69% |
Est @ -4.48% |
Est @ -2.24% |
Est @ -0.67% |
Est @ 0.43% |
|
Present Value (£, Millions) Discounted @ 13% |
UK£0.2 |
UK£2.6 |
UK£4.4 |
UK£3.2 |
UK£2.5 |
UK£2.0 |
UK£1.7 |
UK£1.5 |
UK£1.3 |
UK£1.1 |
(“Est” = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = UK£20m